Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...48495051525354555657585960»
  • ||||||||||  Trial completion date, Trial primary completion date:  Acromegaly: Patient And Physician Perspectives (clinicaltrials.gov) -  Sep 14, 2018   
    P=N/A,  N=300, Recruiting, 
    Recruiting --> Active, not recruiting Trial completion date: Dec 2018 --> May 2019 | Trial primary completion date: Sep 2018 --> Dec 2018
  • ||||||||||  octreotide acetate / Generic mfg.
    Trial completion, Phase classification:  Ultrasound Guided Octreotide LAR Injection in Acromegaly (clinicaltrials.gov) -  Sep 11, 2018   
    P4,  N=15, Completed, 
    Trial completion date: Dec 2018 --> May 2019 | Trial primary completion date: Sep 2018 --> Dec 2018 Recruiting --> Completed | Phase classification: PN/A --> P4
  • ||||||||||  Enrollment open:  Acromegaly: Patient And Physician Perspectives (clinicaltrials.gov) -  Sep 11, 2018   
    P=N/A,  N=300, Recruiting, 
    Recruiting --> Completed | Phase classification: PN/A --> P4 Not yet recruiting --> Recruiting
  • ||||||||||  Trial completion, Trial completion date, Surgery:  Rhinological Outcomes in Endonasal Pituitary Surgery (clinicaltrials.gov) -  Aug 22, 2018   
    P=N/A,  N=235, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Dec 2017 --> Dec 2015
  • ||||||||||  New trial, Surgery:  Sleep Apnea in Acromegaly After Surgery (clinicaltrials.gov) -  May 18, 2018   
    P=N/A,  N=50, Recruiting, 
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment closed, Enrollment change:  The Treatment and Natural History of Acromegaly (clinicaltrials.gov) -  Apr 30, 2018   
    P=N/A,  N=117, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=99999999 --> 117
  • ||||||||||  Trial completion date, Trial primary completion date:  Treatment Patterns and Treatment Outcomes for Acromegaly (clinicaltrials.gov) -  Apr 12, 2018   
    P=N/A,  N=520, Recruiting, 
    Recruiting --> Active, not recruiting | N=99999999 --> 117 Trial completion date: Jul 2017 --> Jul 2019 | Trial primary completion date: Jul 2017 --> Jul 2018
  • ||||||||||  NN1213 / Novo Nordisk
    Phase classification:  The Treatment and Natural History of Acromegaly (clinicaltrials.gov) -  Mar 30, 2018   
    P,  N=99999999, Recruiting, 
    Active, not recruiting --> Completed Phase classification: P=N/A --> P
  • ||||||||||  lignocaine / Generic mfg.
    Enrollment open, Phase classification:  ultradian: Dynamic Hormone Diagnostics in Endocrine Disease (clinicaltrials.gov) -  Feb 23, 2018   
    P=N/A,  N=350, Recruiting, 
    Trial primary completion date: Jul 2024 --> Jun 2023 | Trial completion date: Jul 2024 --> Jun 2023 | Initiation date: Dec 2012 --> Jan 2013 Not yet recruiting --> Recruiting | Phase classification: P2/3 --> PN/A
  • ||||||||||  Enrollment open, Trial initiation date, Trial primary completion date:  SUM: Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly Cardiomyopathy (clinicaltrials.gov) -  Jan 30, 2018   
    P2,  N=15, Recruiting, 
    Active, not recruiting --> Completed | N=20 --> 8 | Trial primary completion date: Sep 2015 --> Mar 2014 Not yet recruiting --> Recruiting | Initiation date: Nov 2015 --> Jul 2016 | Trial primary completion date: Apr 2017 --> Jan 2019
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Enrollment open, Trial initiation date:  I-Con Study: Strict IGF-1 Control in Acromegaly (clinicaltrials.gov) -  Sep 6, 2017   
    P3,  N=35, Recruiting, 
    Trial primary completion date: Apr 2019 --> Jun 2018 Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> Jul 2017
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    Biomarker, Trial primary completion date:  Tissue Biomarker for Pegvisomant Action (clinicaltrials.gov) -  Aug 22, 2017   
    P=N/A,  N=8, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Nov 2017 Trial primary completion date: Dec 2012 --> Mar 2013
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
    Trial termination, Surgery:  A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. (clinicaltrials.gov) -  Aug 18, 2017   
    P4,  N=4, Terminated, 
    Trial primary completion date: Dec 2012 --> Mar 2013 Completed --> Terminated; Didn't enroll enough subjects
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    New trial:  Bone MicroArchitecture in Acromegaly (clinicaltrials.gov) -  Jul 21, 2017   
    P=N/A,  N=25, Recruiting, 
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
    Biomarker, Trial completion:  SOPRANo: Somatuline Predictive Factors in Acromegaly and NET (clinicaltrials.gov) -  Jul 17, 2017   
    P=N/A,  N=156, Completed, 
    N=150 --> 100 | Trial primary completion date: Jun 2017 --> Sep 2017 Active, not recruiting --> Completed
  • ||||||||||  Enrollment closed, HEOR:  Acromegaly Treatment Quality of Life Study (clinicaltrials.gov) -  Mar 3, 2017   
    P=N/A,  N=134, Active, not recruiting, 
    Active, not recruiting --> Completed | N=200 --> 251 Recruiting --> Active, not recruiting
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
    Trial completion:  LANTERN: Efficacy and Safety of Lanreotide Autogel (clinicaltrials.gov) -  Feb 27, 2017   
    P3,  N=128, Completed, 
    Trial primary completion date: Jan 2018 --> Aug 2018 Active, not recruiting --> Completed